Pfizer Inc vs Ryanair Holdings plc — how do they compare? Pfizer Inc trades at $27.88 (market cap $158.39B), while Ryanair Holdings plc trades at $54.19 (market cap $27.58B). The key difference: Pfizer Inc is far larger — about 5.7× Ryanair Holdings plc's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | RYAAY | |
|---|---|---|
Market Cap | $158.39B | $27.58B |
Volume | 29,869,932 | — |
Sector | Health | Industrials |
52-Week High | $29.02 | $73.82 |
52-Week Low | $23.60 | $53.24 |
Enterprise Value | $209.89B | $24.53B |
Dividend Yield | 6.19% | 1.65% |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
RYAAY trades at $54.37, down 1.79% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth trends. Recent news highlights operational challenges including traffic outlook reductions and cost pressures from unhedged fuel. Cash flow remains positive from operations but net cash flow turned negative in 2025 and 2026 projections.
The outlook is cautious due to near-term headwinds from fuel costs and competitive pricing, but long-term fundamentals remain solid with attractive valuation multiples. Investment opportunity exists for value-oriented investors given low P/E of 13.09 and strong profitability metrics. Key risks include oil price volatility and winter capacity constraints affecting profitability.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →